BRISTOL MYERS SQUIBB CO(BMY)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #330 of 2,879 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
BMY Stock Analysis & AI Quality Score
AI stock analysis and institutional research for BRISTOL MYERS SQUIBB CO (BMY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BMY at 70.1/100 on a 32-signal composite quality model, placing it at rank #330 of 2,879 stocks — the top 25% of the AI-ranked universe. BMY scores in the top quartile across revenue scale (97.1), profitability (86.3), balance sheet strength (85.9). Areas of concern include institutional flow (17.5) and earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), BRISTOL MYERS SQUIBB CO reports quarterly revenue of $11.5B, net income of $2.7B, free cash flow of $757.0M. Top institutional holders of BMY by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. BMY trades on the NYSE exchange and files with the SEC under CIK 14272. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BMY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BRISTOL MYERS SQUIBB CO directly from SEC EDGAR. BRISTOL MYERS SQUIBB CO's 13F Pro composite quality score has ranged between 47 and 77 since 2021, currently 70.1 — an improving long-term trajectory across 28 quarterly and live scoring snapshots.
What's Driving BMY's Business? Latest 10-Q Breakdown
✓ 36/36 datapoints verifiedAI-extracted from BRISTOL MYERS SQUIBB CO's 10-Q filed 2026-04-30 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Bristol-Myers Squibb reported Q1 2026 revenues of $11.5B (+3% YoY), with Growth Portfolio sales up 12% to $6.2B and Eliquis revenue surging 16% to $4.1B, offset by generic erosion in legacy products.
Biggest Revenue Drivers
Total revenue: $11,489M+3% YoY
Higher demand across products including Camzyos (+97%), Cobenfy (+107%), Breyanzi (+56%), Reblozyl (+16%), and Opdualag (+17%).
Eliquis increased 16% but offset by generic erosion in Revlimid (-63%), Pomalyst/Imnovid (-22%), Sprycel (-58%), and Abraxane (-53%).
Includes alliance revenues of $94M and other revenues of $227M.
Largest Expense Items
Higher alliance profit sharing and unfavorable product mix.
IPRD impairment charges of $410M for radiopharmaceutical and oncology assets, partially offset by cost savings from restructuring.
Lower amortization from Pomalyst product right fully amortized in Q4 2025.
Higher investments in new product launches, partially offset by cost savings from strategic productivity initiative.
Margins: Gross margin pressure reflected in cost of products sold increasing 13% despite revenue up only 3%, driven by higher alliance profit sharing and product mix changes. Operating performance benefited from lower amortization expense of $393M YoY but offset by elevated IPRD impairment charges of $410M.
Watch Items from the Filing
- Generic erosion accelerating: Revlimid revenue collapsed 63% YoY; Pomalyst/Imnovid down 22%; Sprycel down 58%; Abraxane down 53%; volume-limited generic lenalidomide licenses became unlimited as of January 31, 2026.
- IRA pricing pressure: Eliquis subject to maximum fair price effective January 1, 2026; Pomalyst selected for pricing negotiation effective 2027; Orencia selected for negotiation beginning 2028; U.S. Government Agreement requires free Eliquis to Medicaid and pricing discounts on multiple products.
- Three largest U.S. customers represented 70% of total trade receivables as of March 31, 2026 (versus 75% prior year), indicating concentration risk in U.S. distribution.
- Contingent Value Rights litigation ongoing: plaintiff challenging BMS's acquisition of Celgene seeking $6.4B potential obligation related to Breyanzi approval; court denied jurisdictional motion in December 2025; additional securities litigation and Eliquis patent litigation across multiple European jurisdictions.
- Strong pipeline progression: FDA accepted NDA for iberdomide in RRMM (PDUFA August 2026); positive Phase III results for mezigdomide in RRMM; positive Phase III Camzyos data in adolescents; positive Phase II Reblozyl data in Alpha-Thalassemia.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q1 2026
$11.5B
Net Income
Q1 2026
$2.7B
Free Cash Flow
Q1 2026
$757.0M
D/E Ratio
Q1 2026
2.53
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-0.2% YoYNet Income
+178.8% YoYEPS (Diluted)
+178.5% YoYTotal Assets
-2.8% YoYTotal Debt
-7.3% YoYOp. Cash Flow
-6.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $48.19B -0.2% | $48.30B +7.3% | $45.01B -2.5% | $46.16B -0.5% | $46.38B +9.1% | $42.52B |
| Net Income | $7.05B +178.8% | $-8.95B -211.5% | $8.03B +26.8% | $6.33B -9.5% | $6.99B +177.6% | $-9.02B |
| EPS (Diluted) | $3.46 +178.5% | $-4.41 -214.2% | $3.86 +30.8% | $2.95 -5.4% | $3.12 +178.2% | $-3.99 |
| Total Assets | $90.04B -2.8% | $92.60B -2.7% | $95.16B -1.7% | $96.82B -11.4% | $109.31B -7.7% | $118.48B |
| Total Debt | $51.33B -7.3% | $55.35B +13.8% | $48.64B -5.3% | $51.38B -13.0% | $59.03B +3.5% | $57.02B |
| Operating Cash Flow | $14.16B -6.8% | $15.19B +9.6% | $13.86B +6.1% | $13.07B -19.4% | $16.21B +15.3% | $14.05B |
AI Insight: BMY Financial Trends
Bristol Myers Squibb's revenue remains flat around $12B quarterly while debt decreased $11.4B from Q2 2024 peak to Q1 2026.
• Revenue stayed relatively stable, ranging $11.2B-$12.5B across eight quarters with no clear growth trajectory.
• Total debt declined from $62.1B in Q2 2024 to $50.7B in Q1 2026, improving leverage profile.
• Net income volatility persisted with quarterly results ranging from $72M in Q4 2024 to $2.7B in Q1 2026.
• Equity strengthened from $17.0B in Q2 2024 to $20.1B in Q1 2026, reflecting improved capital structure.
⚠ Operating cash flow dropped sharply to $1.1B in Q1 2026, the lowest level in eight quarters.
⚠ Revenue growth remains elusive with Q1 2026 at $11.5B, below year-ago Q1 2025 level of $11.2B.
AI Insight: BMY Ratio Trends
Bristol Myers Squibb delivered strong Q1 2026 performance with operating margin jumping to 28.2% and debt-to-equity improving to 2.53.
• Operating margin surged from 11.8% in Q4 2025 to 28.2% in Q1 2026, marking the highest quarterly level in the dataset.
• ROIC expanded from 8.4% in Q4 2025 to 18.3% in Q1 2026, demonstrating improved capital efficiency.
• Debt-to-equity ratio declined from 3.60 in Q2 2025 to 2.53 in Q1 2026, indicating strengthening balance sheet.
⚠ Quarterly margins show extreme volatility, swinging from 1.4% in Q4 2024 to 28.2% in Q1 2026.
⚠ Q4 quarters consistently show weaker profitability with operating margins of 1.4% and 11.8% respectively.
Get alerted when BMY's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BRISTOL MYERS SQUIBB CO including:
Top Institutional Holders of BMY
BlackRock, Inc.
$10.4B171,682,888 shVANGUARD CAPITAL MANAGEMENT LLC
$8.0B132,320,240 shSTATE STREET CORP
$6.0B98,564,914 shCHARLES SCHWAB INVESTMENT MANAGEMENT INC
$3.7B61,115,373 shGEODE CAPITAL MANAGEMENT, LLC
$3.3B55,286,174 shVANGUARD PORTFOLIO MANAGEMENT LLC
$2.8B46,230,155 shBANK OF AMERICA CORP /DE/
$2.0B32,586,981 shAQR CAPITAL MANAGEMENT LLC
$1.8B29,631,105 shMORGAN STANLEY
$1.8B29,198,554 shAMERIPRISE FINANCIAL INC
$1.6B26,470,718 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $10.4B | 171,682,888 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.0B | 132,320,240 |
| STATE STREET CORP | $6.0B | 98,564,914 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3.7B | 61,115,373 |
| GEODE CAPITAL MANAGEMENT, LLC | $3.3B | 55,286,174 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.8B | 46,230,155 |
| BANK OF AMERICA CORP /DE/ | $2.0B | 32,586,981 |
| AQR CAPITAL MANAGEMENT LLC | $1.8B | 29,631,105 |
| MORGAN STANLEY | $1.8B | 29,198,554 |
| AMERIPRISE FINANCIAL INC | $1.6B | 26,470,718 |
More Healthcare Companies
View all Healthcare →Put BMY on your watchlist
Track score changes the day BRISTOL MYERS SQUIBB CO files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BMY a good stock to buy?
13F Pro's AI-powered analysis of BRISTOL MYERS SQUIBB CO (BMY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BMY are available on the BMY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BMY?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BMY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BRISTOL MYERS SQUIBB CO's investment landscape.